Details of the Drug
General Information of Drug (ID: DMOS864)
Drug Name |
(2-chloro-6-phenoxyphenyl)methanamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-Chloro-6-phenoxybenzylamine; 175136-89-7; (2-chloro-6-phenoxyphenyl)methanamine; CHEMBL203105; AC1MCRJE; rarechem al bw 1398; SCHEMBL112755; AC1Q53T0; 2-chloro-6-phenoxy-benzylamine; CTK4D5311; DTXSID20380412; SNTOZVXKDWQFEW-UHFFFAOYSA-N; MolPort-000-144-285; ZINC159665; ZX-AT024720; 2-aminomethyl-3-chlorodiphenylether; SBB098143; BDBM50178429; (6-chloro-2-phenoxyphenyl)methylamine; 2-chloro-6-phenoxybenzylamine, 95+%; AKOS009159323; Benzenemethanamine,2-chloro-6-phenoxy-; KB-68526; SC-40136; AJ-15516; ACM175136897; DB-030613
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 233.69 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||